Navigation Links
Alternative to Warfarin May Cut Risk of Bleeding
Date:11/15/2009

Dabigatran etexilate does well in trial of atrial fibrillation patients

SUNDAY, Nov. 15 (HealthDay News) -- The anti-clotting drug dabigatran etexilate (Pradaxa) may be more effective and safer than warfarin at preventing clots and stroke in patients with atrial fibrillation, a new Swedish study has found.

Warfarin is effective in preventing blood clots that can cause stroke in patients with atrial fibrillation (abnormal heart rhythm) and other diseases, but the drug has a narrow therapeutic range in which it prevents strokes but doesn't cause bleeding, according to the researchers. This means that effective warfarin treatment requires regular laboratory monitoring to ensure warfarin levels remain in the range that lowers the risk of stroke without increasing the risk of bleeding.

This study included 18,113 atrial fibrillation patients in 44 countries who were randomly selected to receive either oral treatment with standard warfarin (6,022 patients) or dabigatran etexilate at either 110 milligrams (6,015 patients) or 150 milligrams (6,076 patients).

After one to three years of follow-up, 1.69 percent of patients in the warfarin group suffered a stroke or serious clot per year, compared with 1.53 percent and 1.11 percent of patients taking 110-milligram and 150-milligram doses of dabigatran etexilate, respectively, the study authors, from University Hospital in Uppsala, found.

Rates per year of major bleeding were 3.36 percent in the warfarin group and 2.71 percent and 3.11 percent for patients taking 110-milligram and 150-milligram doses of dabigatran etexilate, respectively.

The study was scheduled to be presented Sunday at the American Heart Association's annual meeting in Orlando, Fla.

The patients in the study were an average age of 72 and included some who'd suffered a prior stroke (13 percent), patients with high blood pressure (79 percent), those who'd never taken an oral anti-clotting drug for more than two months (50.4 percent), and those who weren't using an oral anti-clotting drug when they enrolled in the study (34 percent).

Dabigatran etexilate is approved for use in Canada and Europe but not in the United States.

More information

The American Academy of Family Physicians has more about atrial fibrillation.



-- Robert Preidt



SOURCE: American Heart Association, news release, Nov. 15, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
3. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
4. Trade-offs reveal no clear favorites in alternative energy market
5. Clinical trials present better alternatives for dialysis patients
6. New Technology at Unitrin Direct Gives Customers an Alternative to Waiting
7. Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration
8. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
9. After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative
10. Nosefrida Nasal Aspirator - A Parents Alternative to Medicines on the Verge of FDA Ban
11. Paramedics can provide an effective alternative to standard ambulance service in the community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced ... 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a ... Chandler, Arizona. , Dr. Olson says the decision to support the pageant ...
(Date:6/24/2016)... Knoxville, TN (PRWEB) , ... June 24, 2016 ... ... develop population health management skills and infrastructure. Most providers, however, are unsure how ... Population Health Ascend to define a path forward tailored to an ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched ... medication by matching users with high quality water pipes within an ideal price range. ... , Inhale was founded by two brothers, Nick and Mike Hunter, who use medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Seema Daulat, a native Texan and University of ... location as of July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine ... regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: